Biktarvy Must Be Continued Indefinitely for HIV Treatment
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) should be continued indefinitely as lifelong antiretroviral therapy (ART) for HIV infection, not stopped after 60 days following jaw mass excision for lymphoma. The 60-day limitation appears to be a misunderstanding—HIV requires continuous, uninterrupted treatment regardless of concurrent conditions like lymphoma.
Core Principle: HIV Requires Lifelong Treatment
HIV infection necessitates continuous ART without planned interruptions. Stopping antiretroviral therapy leads to viral rebound, immune deterioration, and increased morbidity and mortality 1. The International Antiviral Society-USA guidelines explicitly recommend Biktarvy (bictegravir/TAF/emtricitabine) as a generally recommended initial regimen with evidence rating AIa 1.
ART During Cancer Treatment
Concomitant ART should be continued in patients receiving therapy for HIV-associated lymphoma 2. The EHA-ESMO guidelines (2024) provide a strong recommendation (Level I, Grade A) that antiretroviral therapy must not be interrupted during lymphoma treatment 2. The IAS-USA panel similarly states that ART should be implemented immediately in the setting of newly diagnosed malignancy, with attention to drug-drug interactions (evidence rating BIIa) 1.
Key Management Points:
- Multidisciplinary approach involving an HIV specialist is strongly recommended to prevent drug-drug interactions between chemotherapy and ART 2
- Biktarvy has favorable characteristics for cancer patients: minimal drug interactions, no pharmacologic boosting required, and proven safety 3
- The jaw mass excision itself is not a reason to discontinue HIV therapy
Long-Term Durability and Safety Data
Biktarvy demonstrates exceptional long-term outcomes:
- Five-year data show 98.6% maintained viral suppression with no treatment-emergent resistance 4
- 144-week real-world data demonstrate 90.6% viral suppression with zero permanent discontinuations due to tolerability 5
- 48-month cohort data from Argentina show 95-98% persistence with sustained viral suppression and minimal adverse events 6
Common Pitfall: Misunderstanding Treatment Duration
The confusion about "60 days" may stem from:
- Prophylaxis regimens (like post-exposure prophylaxis) which are time-limited—but this patient has established HIV infection requiring treatment, not prophylaxis 7
- Perioperative concerns—but surgery is not an indication to stop ART
- Chemotherapy duration—but ART continues beyond cancer treatment completion
Monitoring During Continued Therapy
While maintaining Biktarvy indefinitely:
- Viral load monitoring: Check at 1 month after any regimen change, then every 3-6 months 8, 1
- CD4 count: Every 6-12 months once suppressed 8
- Renal function: Monitor creatinine clearance, especially given tenofovir alafenamide component 9
- Drug interactions: Continuously review with oncology team during chemotherapy 2
Hepatitis B Consideration
If this patient has hepatitis B co-infection, stopping Biktarvy is particularly dangerous as it contains emtricitabine and tenofovir alafenamide (both active against HBV). The FDA label warns that severe acute exacerbations of hepatitis B have been reported in patients who discontinued products containing these components 9. Patients must be monitored closely for several months if discontinuation is ever necessary 9.
Bottom Line
There is no clinical rationale for stopping Biktarvy after 60 days post-lymphoma surgery. HIV treatment is lifelong, and interrupting effective ART increases the risk of viral rebound, resistance development, immune decline, and progression to AIDS 1. The patient should continue Biktarvy indefinitely with appropriate monitoring and drug interaction management during any ongoing cancer therapy 2.